diaDexus (DDXS) is a medical diagnostics company, located in South San Francisco, California, focused on the development and commercialization of patent-protected in vitro diagnostic products addressing significant unmet needs in cardiovascular disease.
diaDexus’ first product, the PLAC® Test for Lp-PLA2, helps identify individuals at increased risk of suffering a heart attack or stroke, the #1 and #4 causes of death respectively in the U.S. These events can be prevented through early detection and more aggressive risk-reducing strategies.
For more information, please visit www.diadexus.com.
diaDexus has received FDA clearance to market the PLAC Test as an aid in the prediction of risk for coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. The PLAC Test determines levels of Lp-PLA2 (lipoprotein-associated phospholipase A2) in the blood; individuals with elevated levels of Lp-PLA2 have been shown to have an increased risk of ischemic stroke and coronary heart disease.
